Anebulo Pharmaceuticals Files 8-K
Ticker: ANEB · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1815974
| Field | Detail |
|---|---|
| Company | Anebulo Pharmaceuticals, Inc. (ANEB) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: ANBU
TL;DR
ANBU filed an 8-K, standard reporting, no major news.
AI Summary
Anebulo Pharmaceuticals, Inc. filed an 8-K on October 17, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This filing indicates Anebulo Pharmaceuticals, Inc. is meeting its regulatory reporting obligations with the SEC. It does not disclose new material information that would immediately impact the company's stock.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for regulatory compliance and does not contain any new material information or significant financial disclosures.
Key Players & Entities
- Anebulo Pharmaceuticals, Inc. (company) — Registrant
- October 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- JFL Capital Management (company) — Business and Mail Address
- Lakeway, TX (location) — Business and Mail Address City and State
FAQ
What is the primary purpose of this 8-K filing for Anebulo Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits, as indicated in the filing.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 17, 2024.
Where is Anebulo Pharmaceuticals, Inc. incorporated?
Anebulo Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Anebulo Pharmaceuticals, Inc.?
The principal executive office address for Anebulo Pharmaceuticals, Inc. is 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
Does this 8-K filing disclose any new material financial information or significant business developments?
Based on the provided text, this 8-K filing appears to be a routine regulatory filing and does not explicitly disclose new material financial information or significant business developments beyond the standard reporting categories.
Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-10-17 07:00:25
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ANEB The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 404KB
- ex99-1_002.jpg (GRAPHIC) — 1574KB
- ex99-1_003.jpg (GRAPHIC) — 727KB
- ex99-1_004.jpg (GRAPHIC) — 1038KB
- ex99-1_005.jpg (GRAPHIC) — 1643KB
- ex99-1_006.jpg (GRAPHIC) — 869KB
- ex99-1_007.jpg (GRAPHIC) — 863KB
- ex99-1_008.jpg (GRAPHIC) — 1188KB
- ex99-1_009.jpg (GRAPHIC) — 664KB
- ex99-1_010.jpg (GRAPHIC) — 1015KB
- ex99-1_011.jpg (GRAPHIC) — 1103KB
- ex99-1_012.jpg (GRAPHIC) — 1200KB
- ex99-1_013.jpg (GRAPHIC) — 824KB
- ex99-1_014.jpg (GRAPHIC) — 1005KB
- ex99-1_015.jpg (GRAPHIC) — 817KB
- ex99-1_016.jpg (GRAPHIC) — 1046KB
- ex99-1_017.jpg (GRAPHIC) — 1021KB
- ex99-1_018.jpg (GRAPHIC) — 966KB
- ex99-1_019.jpg (GRAPHIC) — 1157KB
- ex99-1_020.jpg (GRAPHIC) — 596KB
- ex99-1_021.jpg (GRAPHIC) — 1168KB
- 0001493152-24-041362.txt ( ) — 28961KB
- aneb-20241017.xsd (EX-101.SCH) — 3KB
- aneb-20241017_lab.xml (EX-101.LAB) — 33KB
- aneb-20241017_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANEBULO PHARMACEUTICALS, INC. Date: October 17, 2024 By: /s/ Richard Anthony Cunningham Richard Anthony Cunningham Chief Executive Officer ( Principal Executive Officer )